Ohio_Patient_Network

  • Increase font size
  • Default font size
  • Decrease font size
Home

Cannabis Lab Analysis Project

Harborside Health Center, a leader in the medical marijuana dispensary, has taken a huge step forward in bringing modern laboratory technology to the benefit of the medical marijuana patients.  Below is a article from Harborside about the Cannabis lab analysis project.  See FORTUNE magazine article where Harborside Health Center is prominently mentioned.  When medical marijuana becomes a reality here in Ohio, high quality services like Harborside's should be duplicated.  Below is an article from Harborside Health Center.

Harborside Health Center
is pleased to announce it has begun laboratory analysis of its medical cannabis products. This effort has been developed in partnership with the Analytical Laboratory Project, which owns and operates the laboratory facility. All medicinal cannabis products accepted for distribution to Harborside Health Center will be lab tested for safety and potency. For the first time in the 3000-year history of human cannabis consumption, consumers will be provided a scientific assessment of the safety and potency of products prior to ingesting them.

Testing has begun with cannabis flowers and concentrates, and later will include edibles, tinctures, capsules, etc. The testing techniques include gas chromatography/mass spectrometry, gas chromatography/flame ionization detection, and plate culture analysis. Over the course of the past year, the lab has developed its analytical methods in partnership with respected bio-chemists from some of the Bay Area's most prestigious institutions.The testing program has two main components: safety screening and potency quantification. Safety screening analyzes and detects contamination of pathogenic molds, which can threaten the health of patients with compromised immune systems. Potency quantification provides the percentages of three major cannabinoids: THC, CBD, and CBN. Later stages of the program will include the use of patient surveys to develop a comprehensive database of the efficacy of medical cannabis.

Harborside Health Center patients are able to access the testing results in three ways: labels in display cases, labels on products, and a book of complete test results. Labels include percentages for THC, CBD, and CBN; and are posted in medicine display cases, as well as affixed to the products themselves. A book containing complete spectrometry reports for each product is available at the service counter for those patients who desire more detailed analytical results. Testing services commenced with an initial launch period to identify and develop the logistics of sample collection and result identification. After these issues are fully addressed, the testing service will be made widely available to other medical cannabis collectives, and individual patients. These services will include an independent certification component, so patients can be assured that the medicine they are purchasing has been tested.

Last Updated on Tuesday, 29 September 2009 01:37  

Medical Marijuana News

Maternal Tobacco and Alcohol Use, But Not Marijuana, Associated With Psychotic Symptoms In Offspring, Study Says

Wales, United Kingdom: The maternal use of tobacco and alcohol during pregnancy is linked with increased incidences of psychotic symptoms in adolescents, according to the results of a longitudinal study published in the October issue of The British Journal of Psychiatry.

Investigators at the University of Bristol in Great Britain assessed whether maternal use of tobacco, alcohol, or cannabis during pregnancy increased the risk of psychotic symptoms in their offspring. Researchers examined the drug use habits of the mothers of over 6,300 adolescents – approximately 12 percent of which exhibited some symptoms of psychosis.

Authors concluded: "Frequency of maternal tobacco use during pregnancy was associated with increased risk of suspect or definite psychotic symptoms (in offspring.) Maternal alcohol use shows a non-linear association with psychotic symptoms, with this effect almost exclusively in the offspring of women drinking >21 units (approximately a half-pint of beer or a glass of wine) weekly. Maternal cannabis was not associated with psychotic symptoms."

For more information, please contact Paul Armentano, NORML Deputy Director, at: paul@norml.org. Full text of the study, "Maternal tobacco, cannabis and alcohol use during pregnancy and risk of adolescent psychotic symptoms in offspring," appears in the British Journal of Psychiatry.